Nile Therapeutics appoints Darlene Horton as CMO

Friday, June 22, 2012 10:19 AM

Nile Therapeutics, a San Mateo, Calif.-based biopharmaceutical company that develops novel therapeutics for heart failure patients, has appointed Darlene Horton, M.D. as its chief medical officer.

Horton was previously served as CMO of Itero Biopharmaceuticals, a venture-backed company that developed and out-licensed a biosimilar protein therapeutic. Prio to Itero, she served as senior vice president of clinical research at Scios, a Johnson & Johnson company. During Horton’s 12 year tenure at Scios, she was the clinical lead for Natrecor, a commercial product indicated for the treatment of acute heart failure. Following the acquisition of Scios by J&J, Horton also served as the head of the Cardiovascular Therapeutic Area Center of Excellence for all of J&J pharmaceutical companies.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 21

Healthcare IPOs soar in first quarter

Survey compares 'push/pull' tactics in patient recruitment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs